Ticker Symbol: EKO - TSX Venture Exchange
MONTREAL, Dec. 12 /CNW Telbec/ - Noveko International Inc. ("Noveko" or
the "Company") announces that the members of its Board of Directors have
approved, effective today, December 12, 2007, the grant of 200,000 stock
options to key employees of the Company, entitling them to purchase
Class A shares at the price of $9.68, representing the closing price of the
Class A shares on December 11, 2007. This grant of stock options is
implemented pursuant to the terms of the Stock Option Plan of the Company
currently in effect.
At Noveko's Annual General and Special Meeting of Shareholders held
today, December 12, 2007, shareholders approved the ratification of the
resolution of the Board of Directors adopted on November 9, 2007 and
increasing the number of shares that may be subscribed pursuant to options
granted or to be granted pursuant to the Stock Option Plan, from
8,242,776 Class A shares to 10,698,780 Class A shares.
Noveko International Inc. currently has four subsidiaries: S.A.S. ECM,
Noveko Inc., Laboratoire SyMa Inc. ("SyMa") and Bolduc Leroux Inc. ("BLI").
ECM specializes in the design and marketing of portable real-time ultrasound
scanners for use in veterinary and human medicine. Noveko Inc. develops the
Company's biomedical and environmental business, specifically its patented
antimicrobial filtration technology and derivative products (Noveko(TM)
antimicrobial face masks and air filters). SyMa specializes in the manufacture
of sanitizers, more specifically the antimicrobial products (for hands, feet
and surfaces) sold under the Azuro(TM) trademark. For its part, BLI
specializes in the custom processing and distribution of steel products based
on client specifications and designs. It has also developed and markets a line
of downdraft particle extraction tables for various markets. Operating since
September 2002, the Company was listed on the TSX Venture Exchange on
February 3, 2004.
The information set forth in this press release includes certain
forward-looking statements. Such statements are based on assumptions exposed
to major risks and uncertainties. Although Noveko deems the expectations
reflected in these forward-looking statements to be reasonable, the Company
cannot provide any guarantee as to the materialization of the expectations
reflected in these forward-looking statements. The TSX Venture Exchange has
not reviewed and does not accept responsibility for the adequacy or accuracy
of this release.
For further information:
For further information: André Leroux, Chairman of the Board and Chief
Executive Officer, Noveko International Inc., (514) 344-3030; Alain Bolduc,
President and Chief Operating Officer, Noveko International Inc., (514)